Johnson and Johnson Stock Rally: Analyst Upgrades and Dividend Growth Signal Strength

# Johnson & Johnson (JNJ) Stock Analysis: Analyst Upgrades Push Price Target to $250+ | February 2026 Update **Podcast Episode Description:** Dive into the latest Johnson & Johnson (JNJ) stock analysis as shares trade around $242-$247 with a massive $584 billion market cap. This episode breaks down recent bullish analyst moves, including TD Cowen's price target upgrade to $250, Wells Fargo's overweight rating at $240, and RBC Capital's ambitious $255 target. **Key highlights covered:** - **Stock Performance:** JNJ gained 0.83% on February 20, 2026, closing at $246.90 - **Analyst Consensus:** Multiple firms upgrade ratings with buy recommendations - **Dividend News:** Quarterly dividend increased to $1.30 per share (2.1% yield) - **Trading Volume:** 353,358 shares traded on February 19 - **Potential Catalysts:** Upcoming oncology data and rumored $20B orthopedics sale - **Risk Factors:** Ongoing talc litigation considerations Whether you're a long-term investor or actively trading pharmaceutical stocks, this episode provides essential market insights on one of healthcare's biggest players. Learn why major financial institutions are raising price targets and what technical indicators suggest for JNJ's future. **Perfect for:** Healthcare investors, dividend stock enthusiasts, pharmaceutical sector analysts, and value investors seeking large-cap stability. *Subscribe for regular stock market updates and financial analysis. A Quiet Please production.* **#JNJStock #JohnsonAndJohnson #StockMarket #DividendStocks #HealthcareStocks #InvestingPodcast #StockAnalysis #PharmaceuticalStocks** For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX